Reviews of sessions from HOPA Ahead 2019.
Recent clinical trial findings suggest advances in the treatment of patients with hematologic malignancies including multiple myeloma, lymphoma, and leukemia, according to a review presented by Kathy Hogan Edwards, BS, PharmD, BCPS, BCOP, a Clinical Pharmacy Specialist, Affiliate Associate Professor at the Medical University of South Carolina. Read more.
The process of performing and interpreting tumor genomics for use in an actionable treatment plan is vital in oncology practice, according to a presentation given by Christine M. Walko, PharmD, BCOP, FCCP, Personalized Medicine Specialist, and Chair of the Clinical Genomic Action Committee (CGAC) of the Moffitt Cancer Center in Tampa, FL. Read more.
Recent advancements in research continue to improve breast cancer outcomes across all subsets of the disease, according to a review presented by Sandra Cuellar, PharmD, BCOP, Clinical Assistant Professor, Pharmacy Practice at the University of Illinois at Chicago College of Pharmacy, and a Clinical Oncology Pharmacist at the University of Illinois Hospital & Health Sciences System. Read more.
There exist several barriers to access investigational cancer therapies outside of clinical trials, and many of these barriers have gone unaddressed, according to a review presented by R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, Associate Professor and Director at the Emory Winship Cancer Institute. Read more.
New advances in treatment options for Chronic Lymphocytic Leukemia (CLL) were examined in the presentation given by Alison Duffy, PharmD, of the Maryland University School of Pharmacy, at the 2019 Hematology/Oncology Pharmacy Association Annual Conference in Fort Worth, TX. Read more.
Sunitinib is effective in those categorized with favorable risk Renal Cell Carcinoma, according to a survey of the current research by Kinjal Parikh, PharmD, associate director of clinical strategy hematology/oncology for Medscape, at the 2019 Hematology/Oncology Pharmacy Association Annual Conference in Fort Worth, TX. Read more.
Brentuximab Vedotin (BV) is effective and safe in patients with advanced staged Hodgkin’s Lymphoma according to the presentation by Brianne Dixon, PharmD, a lymphoma clinical pharmacist for Memorial Sloan Kettering Cancer Center, at 2019 Hematology/Oncology Pharmacy Association Annual Conference in Fort Worth, TX. Read more.
Physicians are especially vulnerable to developing compassion fatigue, which can lead to burnout. As such, these physicians need to take steps ensure they preserve their own physical and mental health, according to a presentation by Justin Baker, MD, an oncologist with St Jude Children’s Research Hospital. Read more.
A recent review presented by Christy S. Harris, PharmD, BCOP, Associate Professor, Pharmacy Practice, MCPHS-Boston, at the 2019 HOPA Annual Conference, presented available data and resources to evaluate potential adverse interactions that complementary and alternative medicines (CAMs) may pose to the health of cancer patients and to assess these therapies’ impact on a clinical trial drug. Read more.
Moderate evidence suggests that using medical marijuana can benefit chemotherapy-induced nausea and vomiting (CINV), as well as anorexia, and educating patients about the appropriate use of medical marijuana can maximize outcomes, according to a review presented by Lisa M. Holle, PharmD, BCOP, FHOPA, Associate Clinical Professor at UConn School of Pharmacy, and Associate Professor at UConn School of Medicine, presented at the 2019 HOPA Annual Conference. Read more.
Are “Silver Survivors” Too Old for Treatment? How Chronologic and Functional Age Can Influence Treatment-Related Effects
There exist unique challenges with respect to managing and treating the elderly with cancer, and functional age, determined by geriatric assessment (GA) can influence treatment related effects and health outcomes, according to research presented at the 2019 HOPA Annual Conference by Ginah Nightingale, PharmD, BCOP, Associate Professor of the Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University. Read more.
Prostate cancer screening with prostate-specific antigen (PSA) and digital rectal exams should be a shared decision beginning at age 45-55 years old and drugs such as apalutamide and enzalutamide therapy are effective at slowing the spread of the disease, according to research presented at the 2019 HOPA Annual Conference by Lisa M. Holle, PharmD, BCOP, FHOPA, an Associate Clinical Professor at UConn School of Pharmacy and an Associate Professor at UConn School of Medicine. Read more.
This message is being sent by HOPA on behalf of an external organization. HOPA does not endorse any information or recommendations contained herein nor does it verify the accuracy of the content of this third-party communication. The information presented in this message is not meant to serve as a guideline for patient management. Any procedures, medications, or other course of diagnosis or treatment discussed or suggested should not be used by clinicians without evaluation of their patients' conditions and consideration of possible contraindications. Please review any applicable manufacturer's product information.